Biolinq

Biolinq (formerly Electrozyme) is a medical device developer that produces wearable biosensors and a glucose monitoring platform. The company’s flagship product consists of a press-on wearable patch in the shape of a small hexagon (the size of a nickel). Its non-invasive approach combined with multiplexed sensing capabilities provide real-time biosensor feedback, which according to a feasibility study can continuously track glucose levels for up to seven days.

The product contains micro-array biosensors that measure interstitial fluid glucose levels from the outer layer of the skin for patients with diabetes. The company claims the micro-array biosensor is 25x smaller than conventional glucose sensors. It collects glucose and other biomarker information, including hydration levels, electrolyte balance, and the possibility of heat exhaustion. The microchip inside transmits data via Bluetooth to a smartphone app, and potentially other devices. Additionally, it incorporates a proprietary integrated display on its device. The product is an investigational device that is yet to receive FDA approval.

Key customers and partnerships

In June 2023, the company entered into a license agreement with Taisho Pharmaceutical to commercialize Biolinq’s glucose monitoring products in Japan.

Funding and financials

In April 2024, the company raised USD 58 million in a funding round led by Alpha Wave Ventures. The funds were allocated towards a pivotal clinical trial in the US which assesses Biolinq's proprietary intradermal glucose sensor.